



The Libyan International Medical University
Faculty of Basic Medical Science



Correlation between diabetes and heptites C

Bushra elraid

2160

Supervised by: Basma faraj

Assisted by: Raihan alaobydi

Report Submitted to fulfill the requirements for Scientific Research Activity

Date of Submission: 12/3/ 2019

Abstract

The highest Hepatitis C Virus (HCV) prevalence in the world occurs in Egypt. Several studies from different parts of the world have found that 13% to 33% of patients with chronic HCV have associated diabetes, mostly type II Diabetes Mellitus (DM). In Egypt the prevalence of DM is 25.4% among HCV patients. Therefore, it is important to identify the magnitude of the problem of diabetes in order to optimize the treatment of chronic hepatitis C. The objective of this report was to evaluate the prevalence of DM and other extrahepatic (EH) manifestations among patients with different HCV morbidity stages including asymptomatic, chronic hepatic and cirrhotic patients. In this study, 289 HCV patients older than 18 were selected as cases. Also, 289 healthy controls were included. Laboratory investigations including Liver Function tests (LFT) and blood glucose level were done. Also serological assays including cryoglobulin profile, rheumatoid factor, antinuclear antibody, HCV-PCR were performed. Out of 289 HCV cases, 40 (13.84%) were diabetic. Out of 289 healthy controls, 12 (4.15%) were diabetic. It was found that the diabetic HCV group mean age was [48.1 (\pm 9.2)]. Males and urbanians represented 72.5% and 85% respectively. Lower level of education was manifested in 52.5% and 87.5% were married. In the nondiabetic HCV group mean age was [40.7 (\pm 10.4)]. Males and urbanians represented 71.5% and 65.5% respectively. secondary and higher level of education was attained in 55.4% and 76.7% were married. Comparing between the diabetic HCV group and the non diabetic HCV group, age, residence and alcohol drinking were the only significant factors affecting the incidence of diabetes between the two groups. There was no significant difference regarding sonar findings although cirrhosis was more prevalent among diabetic HCV cases and the fibrosis score was higher in diabetic HCV patients than among the non diabetic HCV cases. The diabetic patients in the

HCV group were older, more likely to have a history of alcohol drinking than the non diabetic HCV cases. Age and alcohol drinking are factors that could potentially contribute to the development of type 2 diabetes. Logistic regression analyses showed that age and residence in urban regions were the predictive variables that could be associated with the presence of diabetes. Alcohol consumption was not a significant predictive factor.

Introduction

The highest Hepatitis C Virus (HCV) prevalence in the world occurs in Egypt at an estimated 12% among the general population [1] and reaches 40% in persons 40 years of age and above in rural areas [2]. HCV Genotype 4 is the predominant genotype being isolated from up to 91% of HCV-infected persons in Egypt [3]. The origin of the HCV epidemic in Egypt has been attributed to intravenous schistosomiasis treatment in rural areas in the 1960s-70s⁴. Although HCV targets at the liver, it has become interestingly

evident that HCV can induce diseases of many organs. Cacoub et al. [5] reported that 38% of patients with HCV would manifest at least one extrahepatic manifestation during the illness. Extrahepatic (EH) manifestations associated with HCV infection include endocrinological manifestations such as diabetes mellitus (DM) [6] and thyroiditis [7], rheumatologic manifestations such as arthralgias, arthritis [8] and mixed cryoglobulinemia [9]. The prevalence of clinically significant EH manifestations is relatively low, but can be associated with significant morbidity and even mortality. An awareness and recognition of these manifestations is of paramount importance in facilitating early diagnosis and management of these complications. 10 Type 2 diabetes (T2D) is a major public health problem worldwide as people become more obese and live a more sedentary lifestyle , This

is in agreement with studies on T2D in noninfected individuals as well as patients infected with other HCV genotypes. The following risk factors are strongly associated with T2D: family history, body fat distribution, age, sex, smoking, and physical activity ,In Egypt the prevalence of DM was 25.4% among HCV patients [17]. Chronic hepatitis C patients are three times more likely to develop DM than HCV seronegative patients ,Therefore, it is important to identify the magnitude of the problem of diabetes in order to optimize the treatment of chronic hepatitis C.

Aim The objective of this study was to evaluate the prevalence of DM and other EH manifestations among patients with different HCV morbidity stages

Materials and Methods

The current research represents a study where patients with chronic HCV infection attending the outpatient clinic of Kasr El-Aini Hospital, Cairo University (KAH), National Hepatology and Tropical Medicine Research Institute (NHTMRI) and Viral Hepatitis Research Laboratory (VHRL) were interviewed. Patients were subjected to a questionnaire to screen those having EH manifestations and general examination. Patients were referred to rheumatologist, dermatologist for further assessment according to their clinical complaints. Laboratory investigations included complete blood picture, liver function tests and blood glucose. Abbott AxSYM System HCV version 3.0 was used for HCV Ab detection followed by In-house RT-PCR 10 for confirmation. Liver function tests (LFT) were carried out using Beckman Synchron CX4 Delta Clinical System (U.S.A.). Serological assay included cryoglobulin profile, rheumatoid factor, antinuclear antibody and HCV-PCR to assess viral load. Abdominal ultrasonography and biopsy was available from some of the patients.

Only HCV patients who were elder than 18 years and had their antibody profile positive for HCV were included as cases. Patients with decompensated liver disease, cancer, on interferon therapy, having end stage renal disease or coexisting viral infection like hepatitis B surface antigen positive patients, pregnant females were excluded from the research. Controls were with normal liver function tests, no serological evidence of HCV and no recent illness.

Results

The mean age of cases (\pm Standard deviation) was 41.7 (\pm 10.6) with age range 19 to 65 years old. 71.6% were males and 28.4% females. Over two-thirds (68.2%) of cases were from urban regions with 45.7% of them did not complete their secondary education. Regarding their occupation, most of the study sample were skilled workers (29.1%), employees (22.8%), housewives (20.4%), students (1.0%) and others (26.9%). 21.4% of them were current smokers, 5.2% were shisha smokers and 7.0% alcohol drinkers, at least one EH manifestation was shown in 63.3% of HCV cases. Cryoglobulinemia was found positive in 22 patients (7.6%). Rheumatologic manifestations were in 18.4% and dermatologic manifestations in 9.6% of the HCV cases. Xerostomia and pruritis were the most prevalent rheumatologic and dermatological manifestation respectively.

The mean age of HCV diabetic cases (\pm SD) [48.1 (\pm 9.2)] was statistically significantly higher than that of HCV nondiabetics [40.7 (\pm 10.4)] (P value = 0.001). Gender, level of education, marital status and occupation did not affect the incidence of diabetes among HCV cases (P values = 0.90, 0.35, 0.13 and 0.46 respectively). However, current residence did affect the incidence of DM. 85% of diabetic HCV cases and 65.5% of non diabetic HCV cases were from urban regions and this difference was statistically significant. Regarding special habits, diabetic HCV cases

were more often found to smoke shisha & drink alcohol than non diabetics. However, they smoke less than nondiabetic HCV cases. The difference was statistically significant regarding alcohol drinking only.

Diabetic cases were more prone to have cirrhosis than nondiabetic HCV cases. Also their stage of liver fibrosis and inflammation was more severe than nondiabetic HCV cases. However, the difference was not statistically significant between diabetic and nondiabetic HCV cases regarding liver condition. There was no significant difference between diabetic and non-diabetic HCV cases regarding the laboratory findings.

The mean age of non-diabetic HCV cases (\pm Standard deviation) was 40.7 (\pm 10.4) with age range 19 to 65 years old which was less than the diabetic HCV cases. Their mean age (\pm Standard deviation) was 48.1 (\pm 9.2) with age range 29 to 65 years old. The mean age of non-diabetic controls (\pm Standard deviation) was 41.6 (\pm 11.9) with age range 21 to 65 years old. Diabetic nonHCV controls were elder in age than non-diabetic controls .

Regarding blood sugar status, it was found that 53 (7.7%) patients were found to be diabetic while 638 (92.3%) were non-diabetic. The difference was statistically significant ($P = 0.0001$). Diabetic cases represented 13.8% of the HCV cases while diabetic controls represented 4.2% of the controls.

Abnormal high ALT, high ALKP and high BIL values was more frequently shown among HCV diabetic cases compared with HCV nondiabetic cases. In non HCV controls, diabetic subjects less frequently showed high AST and ALT. The difference was statistically significant regarding the former parameters.

HCV Diabetics and non HCV Diabetics

The mean age of diabetic HCV cases (\pm SD) was 48.1 (\pm 9.1) with age range 29 to 65 years old. More than one-third of cases fall in the age group 41 to 50 years old and 7.5% only above 60 years old. The mean age of diabetic controls (\pm SD) was 48.6(\pm 8.4) with age range 34 to 65 years old. Males represented 72.5% of the diabetic HCV cases but only 16.7% of diabetic controls. All of the controls were from rural areas while only 15% of the cases were from rural areas. None of the controls completed their secondary education while 47.5% of the cases did.

Regarding abnormal lab characteristics, results had shown that HCV cases were more likely to have high ALT (89.5%) and AST (64.9%) than non-HCV controls (8.3% each).

Discussion

Several strands of evidence have suggested a possible link between HCV infection and an increased prevalence of Type2D 7. Based on case-control studies, the prevalence of DM had been reported in 21% to 50% (a two- to ten-fold increase in prevalence) of patients with chronic HCV infection, which was significantly higher than that in the general population or among patients with other forms of liver diseases 9. This study showed that 13.84% of the HCV patients were type 2 diabetics. These results are comparable to the results of the findings reported by Petit et al. 10 Wang et al. 7 and Veldt et al. 8. Other authors reported higher numbers of diabetics in their studies on HCV patients as El-Zayadi et al. & Lecube et al. 6. They reported prevalence of DM to be 20.9%-29% among HCV patients. Prevalences ranging between 32.5% and 39.8% were reported by Zhao et al⁵ and Chehadeh et al. 4 Differences in the criteria employed in the diagnosis of DM, source of controls,

case definition, sample size and underlying target population may explain much of this observed variability among studies.

Diabetes was shown to be prevalent in 4.15% of the controls who represent age-matched normal population. This result (among controls) is 3-4 times less than what was found in this study (among HCV cases), indicating that HCV patients are a high risk population for DM. In contrast, some studies provided evidence against potential association between these two disorders 9. The prevalence of diabetes in adults in Egypt ranged from 5% in rural communities in the Nile delta to 10% in lower socioeconomic areas of Cairo and over 20% in higher socioeconomic areas in Cairo. Similar results were reported from Italy and India 4, 5. Higher prevalences of DM were reported from other authors 6, This may be attributed to differences in environmental influences, genetic susceptibility and diets.

Sociodemographic characters and special habits of cases and controls

It was noticed that the highest percentage of diabetes (37.5%) was among age group from 41-50 years which was similar to that reported by Wang et al. 3. Conversely, others stated that older age was a potential risk factor for development of DM in HCV patients 1,3. It is interesting to note that older age is associated with more severe liver disease among HCV-infected patients. Studies from Italy and USA referred that HCV increases the prevalence of DM independently of age. These findings have some important clinical and public health implications. They imply that the younger the persons with HCV infection, the greater the risk that they will develop diabetes than will their age-group counterparts without HCV infection. Therefore, screening for and prevention of diabetes in persons with HCV infection could be started earlier than the suggested age of ≥ 45 years for the general

population, especially for those with higher body mass index levels or with other risk factors for diabetes. In addition, young adults with diabetes in communities with a high prevalence of HCV infection could be tested for an underlying HCV infection.

The mean age for HCV DM+ was higher than the mean age for HCV DM- subjects which is interestingly similar to the findings of Giordanino and coworkers ,These findings support the idea that the induction of diabetes in HCV patients is progressive rather than abrupt. Other studies suggest that HCV interferes with glucose metabolism independently of age 5,6,8

Diabetes was more prevalent in females than in males. Our findings are similar to that reported by Huang et al. 6. Males may be more frequently exposed to HCV infection because they have more risk factors including schistosomal infection, shaving beards, accidents, and exposure to operations and blood transfusions. Otherwise, women might be more likely to be associated with HCV clearance and lower rates of HCV-RNA positivity. However, there was no significant difference between diabetic and non-diabetic cases regarding gender which was similar to other studies. Persons with type 2 DM tended to have lower educational attainment. This is in concordance with our study.

Regarding other sonographic features, anti-HCV-positive subjects with sonographic evidence of bright liver, enlarged liver and chronic liver disease had a higher prevalence of T2D compared with patients whose sonographic features were normal. The trend of increasing prevalence of T2D with severity of sonographic stages in anti-HCV-positive subjects implies that viral inflammatory activity, time duration, insulin secretion, insulin sensitivity, and the interaction with other well-known diabetes risk factors appear to play an important role in the development of T2D7.

Diabetes is associated with increased fibrosis in chronic HCV but such an association may be related to the high prevalence of diabetes in patients with cirrhosis. The frequency of diabetes mellitus increased along with pathological staging. The fibrosis score was higher in diabetic HCV patients. The results hereafter were on line with that. In this study, none of the diabetic patients had normal stage of fibrosis. Nearly one half of the diabetic patients (46.7%) showed moderate to severe fibrosis compared to 34.7% in non diabetic HCV patients. The discrepancies among studies may be explained by differences in ethnic background, HCV genotype frequency, and duration and severity of liver disease.

Liver biopsy specimens of diabetic HCV patients showed higher inflammatory activity defined by histological activity index score than the nondiabetic HCV group for moderate and severe stages. That is in line with the results reported by several authors. HCV patients who develop diabetes had more severe liver disease according to both their liver enzymes and biopsy findings. These observations suggest that not HCV infection itself but the resultant ongoing inflammation of the liver might determine a higher risk for DM.

Conclusion

Despite the close relationship between HCV infection and DM, The underlying mechanisms that links diabetes and HCV infection remains conjectural. The increased prevalence of diabetes in chronic hepatitis is unique to HCV and therefore that unique mechanisms may underlie glucose intolerance in HCV patients ,The findings indicate that more severe inflammatory and fibrotic process were associated with diabetes suggest that the pathogenesis of DM in HCV infection may be multifactorial.

Future Work

According to the results of this report which revealed that HCV positive group may be more susceptible to diabetes than HCV seronegative control group however more researches is needed here to give more understanding regarding the exact pathophysiological mechanisms that underlie the occurrence of diabetes in such patients

References

1. Mastoi AA, Devrajani BR, Shah SZ, Rohopoto Q, Memon SA, Baloch M, Qureshi GA, Sami W: Metabolic investigations in patients with hepatitis B and C. *World J Gastroenterol* 2010,16(5):603-7. 10.3748/wjg.v16.i5.603 PubMed Central Article CAS PubMed Google Scholar
2. Medhat A, Shehata M, Magder S: Hepatitis C in a community in Upper Egypt: Risk factors for infection. *Am J Trop Med Hyg* 2002, 66: 633-8. PubMed Google Scholar
3. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL: Genetic epidemiology of HCV throughout Egypt. *J Infect Dis* 2000, 182: 698-707. 10.1086/315786 Article CAS PubMed Google Scholar
4. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, ElKholi T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam L: The role of parenteral antischistosomal therapy in the spread of HCV in Egypt. *Lancet* 2000, 355: 887-91. 10.1016/S0140-6736(99)06527-7 Article CAS PubMed Google Scholar
5. Cacoub P, Renou C, Rosenthal E, Cohen P, Louri I: EH manifestations associated with HCV infection. A prospective multicenter study of 321 patients. The GERMIVIC Groupe d'Etude et de Recherche en Medicine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. *Medicine [Baltimore]* 2000, 79: 47-56. 10.1097/00005792-200001000-00005 Article CAS Google Scholar
6. Mehta SH, Brancati FL, Sulkowski MS, Strathdee S, Szklo M, Thomas DL: Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. *Ann Intern Med* 2000, 133: 592-599. Article CAS PubMed Google Scholar

7. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Ghinoi A, Rotondi M, Ferrannini E: Thyroid disorders in chronic hepatitis C virus infection. *Thyroid* 2006,16(6):563-72. 10.1089/thy.2006.16.563 Article PubMed Google Scholar
8. Sanzone AM, Bégué RE: Hepatitis C and arthritis: an update. *Infect Dis Clin North Am* 2006,20(4):877-89. 10.1016/j.idc.2006.09.010 Article PubMed Google Scholar
9. El-Serag H, Hampel H, Yeh C, Rabeneck L: EH manifestations of hepatitis C among U.S. male veterans. *Hepatology* 2002, 36: 1439-45. Article PubMed Google Scholar
10. Pysopoulos NT, Reddy KR: Extrahepatic manifestations of chronic viral hepatitis. *Curr Gastroenterol Rep* 2001, 3(1):71-8. Review 10.1007/s11894-001-0044-1 Article CAS PubMed Google Scholar